Akerna Corp.
Akerna Corp. KERN Peers
See (KERN) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| KERN | $0.31 | +36.94% | 162.3K | -0.01 | -$44.60 | N/A |
| VEEV | $279.74 | -0.67% | 45.7B | 59.52 | $4.70 | N/A |
| GEHC | $72.75 | +1.07% | 33.3B | 15.28 | $4.76 | +0.18% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | +0.18% |
| DOCS | $60.17 | +2.61% | 11.3B | 54.21 | $1.11 | N/A |
| HQY | $103.99 | -0.18% | 9B | 75.91 | $1.37 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
| BTSG | $22.61 | -1.22% | 4B | 83.74 | $0.27 | N/A |
| BTSGU | $79.22 | -1.85% | 3.8B | N/A | N/A | N/A |
Stock Comparison
KERN vs VEEV Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, VEEV has a market cap of 45.7B. Regarding current trading prices, KERN is priced at $0.31, while VEEV trades at $279.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas VEEV's P/E ratio is 59.52. In terms of profitability, KERN's ROE is -2.22%, compared to VEEV's ROE of +0.14%. Regarding short-term risk, KERN is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs GEHC Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, GEHC has a market cap of 33.3B. Regarding current trading prices, KERN is priced at $0.31, while GEHC trades at $72.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas GEHC's P/E ratio is 15.28. In terms of profitability, KERN's ROE is -2.22%, compared to GEHC's ROE of +0.26%. Regarding short-term risk, KERN is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs GEHCV Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, KERN is priced at $0.31, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas GEHCV's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to GEHCV's ROE of +0.26%. Regarding short-term risk, KERN is more volatile compared to GEHCV. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs DOCS Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, DOCS has a market cap of 11.3B. Regarding current trading prices, KERN is priced at $0.31, while DOCS trades at $60.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas DOCS's P/E ratio is 54.21. In terms of profitability, KERN's ROE is -2.22%, compared to DOCS's ROE of +0.22%. Regarding short-term risk, KERN is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs HQY Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, HQY has a market cap of 9B. Regarding current trading prices, KERN is priced at $0.31, while HQY trades at $103.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas HQY's P/E ratio is 75.91. In terms of profitability, KERN's ROE is -2.22%, compared to HQY's ROE of +0.06%. Regarding short-term risk, KERN is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs SGFY Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, KERN is priced at $0.31, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SGFY's P/E ratio is 70.91. In terms of profitability, KERN's ROE is -2.22%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, KERN is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs RCM Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, RCM has a market cap of 6B. Regarding current trading prices, KERN is priced at $0.31, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas RCM's P/E ratio is -102.21. In terms of profitability, KERN's ROE is -2.22%, compared to RCM's ROE of -0.02%. Regarding short-term risk, KERN is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs BTSG Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, BTSG has a market cap of 4B. Regarding current trading prices, KERN is priced at $0.31, while BTSG trades at $22.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas BTSG's P/E ratio is 83.74. In terms of profitability, KERN's ROE is -2.22%, compared to BTSG's ROE of +0.03%. Regarding short-term risk, KERN is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs BTSGU Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, BTSGU has a market cap of 3.8B. Regarding current trading prices, KERN is priced at $0.31, while BTSGU trades at $79.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas BTSGU's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to BTSGU's ROE of +0.03%. Regarding short-term risk, KERN is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs ONEM Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, KERN is priced at $0.31, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ONEM's P/E ratio is -7.77. In terms of profitability, KERN's ROE is -2.22%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, KERN is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs PRVA Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, PRVA has a market cap of 2.7B. Regarding current trading prices, KERN is priced at $0.31, while PRVA trades at $21.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas PRVA's P/E ratio is 181.25. In terms of profitability, KERN's ROE is -2.22%, compared to PRVA's ROE of +0.02%. Regarding short-term risk, KERN is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs WGS Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, WGS has a market cap of 2.5B. Regarding current trading prices, KERN is priced at $0.31, while WGS trades at $88.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas WGS's P/E ratio is -63.98. In terms of profitability, KERN's ROE is -2.22%, compared to WGS's ROE of -0.17%. Regarding short-term risk, KERN is more volatile compared to WGS. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs PINC Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, PINC has a market cap of 1.8B. Regarding current trading prices, KERN is priced at $0.31, while PINC trades at $21.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas PINC's P/E ratio is 21.43. In terms of profitability, KERN's ROE is -2.22%, compared to PINC's ROE of +0.03%. Regarding short-term risk, KERN is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs PGNY Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, PGNY has a market cap of 1.8B. Regarding current trading prices, KERN is priced at $0.31, while PGNY trades at $20.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas PGNY's P/E ratio is 36.68. In terms of profitability, KERN's ROE is -2.22%, compared to PGNY's ROE of +0.12%. Regarding short-term risk, KERN is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs CERT Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CERT has a market cap of 1.8B. Regarding current trading prices, KERN is priced at $0.31, while CERT trades at $10.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CERT's P/E ratio is -543.00. In terms of profitability, KERN's ROE is -2.22%, compared to CERT's ROE of -0.00%. Regarding short-term risk, KERN is more volatile compared to CERT. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs GDRX Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, GDRX has a market cap of 1.8B. Regarding current trading prices, KERN is priced at $0.31, while GDRX trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas GDRX's P/E ratio is 70.14. In terms of profitability, KERN's ROE is -2.22%, compared to GDRX's ROE of +0.07%. Regarding short-term risk, KERN is more volatile compared to GDRX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs PHR Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, PHR has a market cap of 1.6B. Regarding current trading prices, KERN is priced at $0.31, while PHR trades at $27.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas PHR's P/E ratio is -37.35. In terms of profitability, KERN's ROE is -2.22%, compared to PHR's ROE of -0.23%. Regarding short-term risk, KERN is more volatile compared to PHR. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs NXGN Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, KERN is priced at $0.31, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas NXGN's P/E ratio is -266.00. In terms of profitability, KERN's ROE is -2.22%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, KERN is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs SDGR Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SDGR has a market cap of 1.5B. Regarding current trading prices, KERN is priced at $0.31, while SDGR trades at $20.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SDGR's P/E ratio is -7.82. In terms of profitability, KERN's ROE is -2.22%, compared to SDGR's ROE of -0.45%. Regarding short-term risk, KERN is more volatile compared to SDGR. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs TXG Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, TXG has a market cap of 1.5B. Regarding current trading prices, KERN is priced at $0.31, while TXG trades at $11.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas TXG's P/E ratio is -8.97. In terms of profitability, KERN's ROE is -2.22%, compared to TXG's ROE of -0.22%. Regarding short-term risk, KERN is more volatile compared to TXG. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs AGTI Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, KERN is priced at $0.31, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas AGTI's P/E ratio is -71.79. In terms of profitability, KERN's ROE is -2.22%, compared to AGTI's ROE of -0.01%. Regarding short-term risk, KERN is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs OMCL Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, OMCL has a market cap of 1.3B. Regarding current trading prices, KERN is priced at $0.31, while OMCL trades at $28.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas OMCL's P/E ratio is 62.48. In terms of profitability, KERN's ROE is -2.22%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, KERN is more volatile compared to OMCL. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs TDOC Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, TDOC has a market cap of 1.3B. Regarding current trading prices, KERN is priced at $0.31, while TDOC trades at $7.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas TDOC's P/E ratio is -1.28. In terms of profitability, KERN's ROE is -2.22%, compared to TDOC's ROE of -0.68%. Regarding short-term risk, KERN is more volatile compared to TDOC. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs EVH Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, EVH has a market cap of 1.3B. Regarding current trading prices, KERN is priced at $0.31, while EVH trades at $10.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas EVH's P/E ratio is -8.80. In terms of profitability, KERN's ROE is -2.22%, compared to EVH's ROE of -0.11%. Regarding short-term risk, KERN is more volatile compared to EVH. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs HSTM Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, HSTM has a market cap of 818.1M. Regarding current trading prices, KERN is priced at $0.31, while HSTM trades at $26.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas HSTM's P/E ratio is 42.54. In terms of profitability, KERN's ROE is -2.22%, compared to HSTM's ROE of +0.05%. Regarding short-term risk, KERN is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs CTEV Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CTEV has a market cap of 685.4M. Regarding current trading prices, KERN is priced at $0.31, while CTEV trades at $41.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CTEV's P/E ratio is -0.57. In terms of profitability, KERN's ROE is -2.22%, compared to CTEV's ROE of -5.18%. Regarding short-term risk, KERN is more volatile compared to CTEV. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs NUTX Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, NUTX has a market cap of 669.9M. Regarding current trading prices, KERN is priced at $0.31, while NUTX trades at $120.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas NUTX's P/E ratio is 9.76. In terms of profitability, KERN's ROE is -2.22%, compared to NUTX's ROE of +0.71%. Regarding short-term risk, KERN is more volatile compared to NUTX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs MPLN-WT Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, KERN is priced at $0.31, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to MPLN-WT's ROE of -5.18%. Regarding short-term risk, KERN is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.
KERN vs ACCD Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, KERN is priced at $0.31, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ACCD's P/E ratio is -3.08. In terms of profitability, KERN's ROE is -2.22%, compared to ACCD's ROE of -0.45%. Regarding short-term risk, KERN is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs SHCR Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, KERN is priced at $0.31, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SHCR's P/E ratio is -3.76. In terms of profitability, KERN's ROE is -2.22%, compared to SHCR's ROE of -0.24%. Regarding short-term risk, KERN is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs DH Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, DH has a market cap of 412.2M. Regarding current trading prices, KERN is priced at $0.31, while DH trades at $3.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas DH's P/E ratio is -0.87. In terms of profitability, KERN's ROE is -2.22%, compared to DH's ROE of -1.07%. Regarding short-term risk, KERN is more volatile compared to DH. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs SLGCW Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, KERN is priced at $0.31, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, KERN's ROE is -2.22%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, KERN is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.
KERN vs SLGC Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, KERN is priced at $0.31, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SLGC's P/E ratio is -3.04. In terms of profitability, KERN's ROE is -2.22%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, KERN is more volatile compared to SLGC. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs NRC Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, NRC has a market cap of 383.7M. Regarding current trading prices, KERN is priced at $0.31, while NRC trades at $16.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas NRC's P/E ratio is 16.51. In terms of profitability, KERN's ROE is -2.22%, compared to NRC's ROE of +0.71%. Regarding short-term risk, KERN is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs MPLN Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, KERN is priced at $0.31, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas MPLN's P/E ratio is -0.23. In terms of profitability, KERN's ROE is -2.22%, compared to MPLN's ROE of -5.18%. Regarding short-term risk, KERN is more volatile compared to MPLN. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs SPOK Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SPOK has a market cap of 353M. Regarding current trading prices, KERN is priced at $0.31, while SPOK trades at $17.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SPOK's P/E ratio is 22.29. In terms of profitability, KERN's ROE is -2.22%, compared to SPOK's ROE of +0.10%. Regarding short-term risk, KERN is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs TBRG Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, TBRG has a market cap of 343.4M. Regarding current trading prices, KERN is priced at $0.31, while TBRG trades at $22.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas TBRG's P/E ratio is -18.74. In terms of profitability, KERN's ROE is -2.22%, compared to TBRG's ROE of -0.10%. Regarding short-term risk, KERN is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs SLP Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SLP has a market cap of 340.5M. Regarding current trading prices, KERN is priced at $0.31, while SLP trades at $16.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SLP's P/E ratio is 47.03. In terms of profitability, KERN's ROE is -2.22%, compared to SLP's ROE of +0.04%. Regarding short-term risk, KERN is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs TRHC Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, KERN is priced at $0.31, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas TRHC's P/E ratio is -4.27. In terms of profitability, KERN's ROE is -2.22%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, KERN is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs HCAT Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, HCAT has a market cap of 262.7M. Regarding current trading prices, KERN is priced at $0.31, while HCAT trades at $3.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas HCAT's P/E ratio is -3.28. In terms of profitability, KERN's ROE is -2.22%, compared to HCAT's ROE of -0.20%. Regarding short-term risk, KERN is more volatile compared to HCAT. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs SMFR Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, KERN is priced at $0.31, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SMFR's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to SMFR's ROE of -0.17%. Regarding short-term risk, KERN is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.
KERN vs OPRX Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, OPRX has a market cap of 244.1M. Regarding current trading prices, KERN is priced at $0.31, while OPRX trades at $13.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas OPRX's P/E ratio is -15.71. In terms of profitability, KERN's ROE is -2.22%, compared to OPRX's ROE of -0.13%. Regarding short-term risk, KERN is more volatile compared to OPRX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs SY Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SY has a market cap of 242.3M. Regarding current trading prices, KERN is priced at $0.31, while SY trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SY's P/E ratio is -2.30. In terms of profitability, KERN's ROE is -2.22%, compared to SY's ROE of -0.26%. Regarding short-term risk, KERN is more volatile compared to SY. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs SOPH Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SOPH has a market cap of 211.9M. Regarding current trading prices, KERN is priced at $0.31, while SOPH trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SOPH's P/E ratio is -3.17. In terms of profitability, KERN's ROE is -2.22%, compared to SOPH's ROE of -0.63%. Regarding short-term risk, KERN is more volatile compared to SOPH. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs EUDA Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, EUDA has a market cap of 136.4M. Regarding current trading prices, KERN is priced at $0.31, while EUDA trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas EUDA's P/E ratio is -6.80. In terms of profitability, KERN's ROE is -2.22%, compared to EUDA's ROE of +3.05%. Regarding short-term risk, KERN is more volatile compared to EUDA. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs CPSI Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, KERN is priced at $0.31, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CPSI's P/E ratio is -183.80. In terms of profitability, KERN's ROE is -2.22%, compared to CPSI's ROE of -0.18%. Regarding short-term risk, KERN is more volatile compared to CPSI. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs AMWL Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, AMWL has a market cap of 117.9M. Regarding current trading prices, KERN is priced at $0.31, while AMWL trades at $7.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas AMWL's P/E ratio is -0.74. In terms of profitability, KERN's ROE is -2.22%, compared to AMWL's ROE of -0.48%. Regarding short-term risk, KERN is more volatile compared to AMWL. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs AUGX Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, KERN is priced at $0.31, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas AUGX's P/E ratio is -4.99. In terms of profitability, KERN's ROE is -2.22%, compared to AUGX's ROE of -1.13%. Regarding short-term risk, KERN is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs CCLDO Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CCLDO has a market cap of 110M. Regarding current trading prices, KERN is priced at $0.31, while CCLDO trades at $19.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CCLDO's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to CCLDO's ROE of +0.21%. Regarding short-term risk, KERN is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs CCLD Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CCLD has a market cap of 106.6M. Regarding current trading prices, KERN is priced at $0.31, while CCLD trades at $2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CCLD's P/E ratio is -11.45. In terms of profitability, KERN's ROE is -2.22%, compared to CCLD's ROE of +0.21%. Regarding short-term risk, KERN is more volatile compared to CCLD. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs FORA Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, FORA has a market cap of 64.3M. Regarding current trading prices, KERN is priced at $0.31, while FORA trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas FORA's P/E ratio is -17.17. In terms of profitability, KERN's ROE is -2.22%, compared to FORA's ROE of -0.13%. Regarding short-term risk, KERN is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs CCLDP Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, KERN is priced at $0.31, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CCLDP's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to CCLDP's ROE of +0.21%. Regarding short-term risk, KERN is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs BEAT Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, BEAT has a market cap of 48M. Regarding current trading prices, KERN is priced at $0.31, while BEAT trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas BEAT's P/E ratio is -1.92. In terms of profitability, KERN's ROE is -2.22%, compared to BEAT's ROE of -3.58%. Regarding short-term risk, KERN is more volatile compared to BEAT. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs BEATW Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, BEATW has a market cap of 40.3M. Regarding current trading prices, KERN is priced at $0.31, while BEATW trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas BEATW's P/E ratio is -0.61. In terms of profitability, KERN's ROE is -2.22%, compared to BEATW's ROE of -3.58%. Regarding short-term risk, KERN is more volatile compared to BEATW. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs SNCE Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, KERN is priced at $0.31, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SNCE's P/E ratio is -0.27. In terms of profitability, KERN's ROE is -2.22%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, KERN is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs AKLI Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, KERN is priced at $0.31, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas AKLI's P/E ratio is -0.71. In terms of profitability, KERN's ROE is -2.22%, compared to AKLI's ROE of -0.38%. Regarding short-term risk, KERN is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs SHLT Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, KERN is priced at $0.31, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SHLT's P/E ratio is -3.87. In terms of profitability, KERN's ROE is -2.22%, compared to SHLT's ROE of -0.09%. Regarding short-term risk, KERN is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs SHCRW Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, KERN is priced at $0.31, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, KERN's ROE is -2.22%, compared to SHCRW's ROE of -0.24%. Regarding short-term risk, KERN is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs STRM Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, STRM has a market cap of 22.6M. Regarding current trading prices, KERN is priced at $0.31, while STRM trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas STRM's P/E ratio is -2.33. In terms of profitability, KERN's ROE is -2.22%, compared to STRM's ROE of -0.68%. Regarding short-term risk, KERN is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs RNLX Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, KERN is priced at $0.31, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas RNLX's P/E ratio is -0.33. In terms of profitability, KERN's ROE is -2.22%, compared to RNLX's ROE of +2.93%. Regarding short-term risk, KERN is more volatile compared to RNLX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs LIFW Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, KERN is priced at $0.31, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas LIFW's P/E ratio is -0.02. In terms of profitability, KERN's ROE is -2.22%, compared to LIFW's ROE of -3.08%. Regarding short-term risk, KERN is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs MGRX Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, MGRX has a market cap of 17.9M. Regarding current trading prices, KERN is priced at $0.31, while MGRX trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas MGRX's P/E ratio is -0.39. In terms of profitability, KERN's ROE is -2.22%, compared to MGRX's ROE of -0.73%. Regarding short-term risk, KERN is more volatile compared to MGRX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs ONMD Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ONMD has a market cap of 17.5M. Regarding current trading prices, KERN is priced at $0.31, while ONMD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ONMD's P/E ratio is -1.68. In terms of profitability, KERN's ROE is -2.22%, compared to ONMD's ROE of +0.60%. Regarding short-term risk, KERN is more volatile compared to ONMD. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs BFRGW Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, BFRGW has a market cap of 16.9M. Regarding current trading prices, KERN is priced at $0.31, while BFRGW trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas BFRGW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to BFRGW's ROE of -1.33%. Regarding short-term risk, KERN is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.
KERN vs VSEE Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, VSEE has a market cap of 16.6M. Regarding current trading prices, KERN is priced at $0.31, while VSEE trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas VSEE's P/E ratio is -13.25. In terms of profitability, KERN's ROE is -2.22%, compared to VSEE's ROE of -6.10%. Regarding short-term risk, KERN is more volatile compared to VSEE. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs BFRG Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, BFRG has a market cap of 15.2M. Regarding current trading prices, KERN is priced at $0.31, while BFRG trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas BFRG's P/E ratio is -2.01. In terms of profitability, KERN's ROE is -2.22%, compared to BFRG's ROE of -1.63%. Regarding short-term risk, KERN is more volatile compared to BFRG. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs VSEEW Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, VSEEW has a market cap of 14.4M. Regarding current trading prices, KERN is priced at $0.31, while VSEEW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas VSEEW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to VSEEW's ROE of -6.10%. Regarding short-term risk, KERN is more volatile compared to VSEEW. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs BBLN Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, KERN is priced at $0.31, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas BBLN's P/E ratio is -0.04. In terms of profitability, KERN's ROE is -2.22%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, KERN is more volatile compared to BBLN. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs SCNX Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SCNX has a market cap of 13M. Regarding current trading prices, KERN is priced at $0.31, while SCNX trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SCNX's P/E ratio is 1.59. In terms of profitability, KERN's ROE is -2.22%, compared to SCNX's ROE of +0.19%. Regarding short-term risk, KERN is more volatile compared to SCNX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs INOV Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, INOV has a market cap of 12.6M. Regarding current trading prices, KERN is priced at $0.31, while INOV trades at $31.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas INOV's P/E ratio is 16.28. In terms of profitability, KERN's ROE is -2.22%, compared to INOV's ROE of +0.03%. Regarding short-term risk, KERN is more volatile compared to INOV. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs HCTI Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, HCTI has a market cap of 12.3M. Regarding current trading prices, KERN is priced at $0.31, while HCTI trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas HCTI's P/E ratio is -0.03. In terms of profitability, KERN's ROE is -2.22%, compared to HCTI's ROE of +2.95%. Regarding short-term risk, KERN is more volatile compared to HCTI. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs MSPR Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, MSPR has a market cap of 10.3M. Regarding current trading prices, KERN is priced at $0.31, while MSPR trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas MSPR's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to MSPR's ROE of -3.08%. Regarding short-term risk, KERN is more volatile compared to MSPR. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs ETAO Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, KERN is priced at $0.31, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ETAO's P/E ratio is -0.01. In terms of profitability, KERN's ROE is -2.22%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, KERN is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.
KERN vs HLTH Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, KERN is priced at $0.31, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas HLTH's P/E ratio is -0.02. In terms of profitability, KERN's ROE is -2.22%, compared to HLTH's ROE of -0.88%. Regarding short-term risk, KERN is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.
KERN vs ZCMD Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ZCMD has a market cap of 6.3M. Regarding current trading prices, KERN is priced at $0.31, while ZCMD trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ZCMD's P/E ratio is -10.08. In terms of profitability, KERN's ROE is -2.22%, compared to ZCMD's ROE of -0.03%. Regarding short-term risk, KERN is more volatile compared to ZCMD. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs UPH Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, KERN is priced at $0.31, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas UPH's P/E ratio is -0.07. In terms of profitability, KERN's ROE is -2.22%, compared to UPH's ROE of -1.05%. Regarding short-term risk, KERN is more volatile compared to UPH. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs EUDAW Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, EUDAW has a market cap of 4.7M. Regarding current trading prices, KERN is priced at $0.31, while EUDAW trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas EUDAW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to EUDAW's ROE of +3.05%. Regarding short-term risk, KERN is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.
KERN vs ACON Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ACON has a market cap of 4.1M. Regarding current trading prices, KERN is priced at $0.31, while ACON trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ACON's P/E ratio is -0.62. In terms of profitability, KERN's ROE is -2.22%, compared to ACON's ROE of -1.27%. Regarding short-term risk, KERN is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs PEARW Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, KERN is priced at $0.31, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas PEARW's P/E ratio is -0.00. In terms of profitability, KERN's ROE is -2.22%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, KERN is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.
KERN vs PEAR Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, KERN is priced at $0.31, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas PEAR's P/E ratio is -0.08. In terms of profitability, KERN's ROE is -2.22%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, KERN is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.
KERN vs OTRK Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, OTRK has a market cap of 4.1M. Regarding current trading prices, KERN is priced at $0.31, while OTRK trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas OTRK's P/E ratio is -0.06. In terms of profitability, KERN's ROE is -2.22%, compared to OTRK's ROE of -1.76%. Regarding short-term risk, KERN is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs WGSWW Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, WGSWW has a market cap of 2.2M. Regarding current trading prices, KERN is priced at $0.31, while WGSWW trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas WGSWW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to WGSWW's ROE of -0.17%. Regarding short-term risk, KERN is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.
KERN vs FOXO Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, FOXO has a market cap of 2.2M. Regarding current trading prices, KERN is priced at $0.31, while FOXO trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas FOXO's P/E ratio is -0.03. In terms of profitability, KERN's ROE is -2.22%, compared to FOXO's ROE of -0.01%. Regarding short-term risk, KERN is more volatile compared to FOXO. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs CMAX Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, KERN is priced at $0.31, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CMAX's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to CMAX's ROE of +30.94%. Regarding short-term risk, KERN is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs WORX Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, WORX has a market cap of 1.6M. Regarding current trading prices, KERN is priced at $0.31, while WORX trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas WORX's P/E ratio is -0.48. In terms of profitability, KERN's ROE is -2.22%, compared to WORX's ROE of -0.32%. Regarding short-term risk, KERN is more volatile compared to WORX. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs LIFWZ Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, KERN is priced at $0.31, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to LIFWZ's ROE of -3.08%. Regarding short-term risk, KERN is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs OTRKP Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, OTRKP has a market cap of 1M. Regarding current trading prices, KERN is priced at $0.31, while OTRKP trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas OTRKP's P/E ratio is -0.08. In terms of profitability, KERN's ROE is -2.22%, compared to OTRKP's ROE of -1.76%. Regarding short-term risk, KERN is more volatile compared to OTRKP. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs ICCT Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ICCT has a market cap of 902.3K. Regarding current trading prices, KERN is priced at $0.31, while ICCT trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ICCT's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to ICCT's ROE of -14.51%. Regarding short-term risk, KERN is more volatile compared to ICCT. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs KERNW Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, KERN is priced at $0.31, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas KERNW's P/E ratio is -0.00. In terms of profitability, KERN's ROE is -2.22%, compared to KERNW's ROE of -2.22%. Regarding short-term risk, KERN is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.
KERN vs MSPRZ Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, MSPRZ has a market cap of 116.1K. Regarding current trading prices, KERN is priced at $0.31, while MSPRZ trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to MSPRZ's ROE of -3.08%. Regarding short-term risk, KERN is more volatile compared to MSPRZ. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs LIFWW Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, KERN is priced at $0.31, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas LIFWW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to LIFWW's ROE of -3.08%. Regarding short-term risk, KERN is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs CMAXW Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, KERN is priced at $0.31, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CMAXW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to CMAXW's ROE of +30.94%. Regarding short-term risk, KERN is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs ACONW Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, ACONW has a market cap of 17.8K. Regarding current trading prices, KERN is priced at $0.31, while ACONW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas ACONW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to ACONW's ROE of -1.27%. Regarding short-term risk, KERN is more volatile compared to ACONW. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs MSPRW Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, MSPRW has a market cap of 7.7K. Regarding current trading prices, KERN is priced at $0.31, while MSPRW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas MSPRW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to MSPRW's ROE of -3.08%. Regarding short-term risk, KERN is less volatile compared to MSPRW. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.
KERN vs UTRS Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, UTRS has a market cap of 888. Regarding current trading prices, KERN is priced at $0.31, while UTRS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas UTRS's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to UTRS's ROE of -1.11%. Regarding short-term risk, KERN is more volatile compared to UTRS. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs CERN Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, CERN has a market cap of 0. Regarding current trading prices, KERN is priced at $0.31, while CERN trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas CERN's P/E ratio is 55.84. In terms of profitability, KERN's ROE is -2.22%, compared to CERN's ROE of +0.14%. Regarding short-term risk, KERN is more volatile compared to CERN. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs MTBCP Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, KERN is priced at $0.31, while MTBCP trades at $26.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas MTBCP's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to MTBCP's ROE of +0.21%. Regarding short-term risk, KERN is more volatile compared to MTBCP. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs MTBCO Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, KERN is priced at $0.31, while MTBCO trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas MTBCO's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to MTBCO's ROE of +0.21%. Regarding short-term risk, KERN is more volatile compared to MTBCO. This indicates potentially higher risk in terms of short-term price fluctuations for KERN.
KERN vs SMFRW Comparison
KERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KERN stands at 162.3K. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, KERN is priced at $0.31, while SMFRW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KERN currently has a P/E ratio of -0.01, whereas SMFRW's P/E ratio is N/A. In terms of profitability, KERN's ROE is -2.22%, compared to SMFRW's ROE of -0.17%. Regarding short-term risk, KERN is less volatile compared to SMFRW. This indicates potentially lower risk in terms of short-term price fluctuations for KERN.